Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
“As we develop effective regulatory strategies for our clients’ drug candidates, I am very pleased that Genizon will work alongside us at our clients’ requests,” said
“We believe that we can add significant value to Speid & Associates’ clients through pharmacogenomic studies and analyses using our gene discovery platform and expertise. These enable invaluable insights into drug response, and therefore improve clinical trial outcomes,” said
About Genizon BioSciences
Genizon BioSciences Inc. is a leader in genetic solutions. Genizon discovers genes, genetic biomarkers, biochemical pathways and drug targets that are involved in human disease susceptibility and drug response. These genetic insights allow the development of predictive diagnostics that facilitate personalized medicine. Working with a network of over 1,000 clinical investigators, Genizon has recruited over 47,000 subjects in 25 common diseases, which are analyzed in a unique, integrated high throughput facility that is compliant with GCP and GLP guidelines. Discoveries are translated into clinical practice through collaborative research with academic and clinical leaders. Genizon also provides high throughput, high quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.
For more information visit: www.genizon.com
About Speid & Associates, Inc.
Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in
For more information visit: www.drugstomarket.com
SOURCE Genizon BioSciences Inc.; Speid & Associates, Inc.